KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.95

Decitabine in older patients with AML: quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase 3 trial.

Fabio Efficace, Michal Kicinski, Corneel Coens, Stefan Suciu, Walter J F M van der Velden, Richard Noppeney, Sylvain Chantepie, Laimonas Griskevicius, Andreas Neubauer, Ernesta Audisio, Mario Luppi, Stephan Fuhrmann, Robin Foà, Martina Crysandt, Gianluca Gaidano, Radovan Vrhovac, Adriano Venditti, Eduardus F M Posthuma, Anna Candoni, Frédéric Baron, Olivier Legrand, Andrea Mengarelli, Paola Fazi, Marco Vignetti, Anne Giraut, Pierre W Wijermans, Gerwin Huls, Michael Lübbert

Blood 144(5) 541-551

PMID38717861
PMCID-
DOI10.1182/blood.2023023625
发表日期2024-05-08
入排依据:The report is an original, randomized, phase III trial with a drug intervention, but its primary/key secondary endpoint is health-related quality of life (HRQoL), not a time-to-event efficacy endpoint like OS, PFS, DFS, etc. No Kaplan-Meier survival curves or hazard ratios for time-to-event outcomes are reported or referenced in the abstract. Therefore, it does not meet the requirement for a primary/key secondary time-to-event efficacy endpoint.
摘要

摘要

We hypothesized that fit older patients with acute myeloid leukemia (AML) treated with decitabine (DEC) would report better health-related quality of life (HRQoL) outcomes than those receiving intensive chemotherapy (IC). We conducted a phase 3 randomized trial to compare DEC (10-day schedule) with IC (3+7) in older fit patients with AML. HRQoL was a secondary end point, and it was assessed with the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) in conjunction with its elderly module (EORTC QLQ-ELD14). The following scales were a priori selected for defining the primary end point: physical and role functioning, fatigue, pain, and burden of illness. HRQoL was assessed at baseline, at regeneration from cycle 2, and at 6 and 12 months after randomization, and also before allogeneic hematopoietic stem cell transplantation (allo-HSCT) and 100 days after transplantation. Overall, 606 patients underwent randomization. At 2 months, the risk of HRQoL deterioration was lower in the DEC arm than in the 3+7 arm; 76% (95% confidence interval [CI], 69-82) vs 88% (95% CI, 82-93); odds ratio, 0.43 (95% CI, 0.24-0.76; P = .003). No statistically significant HRQoL differences were observed between treatment arms at the long-term evaluation combining assessments at 6 and 12 months. HRQoL deteriorations between baseline and after allo-HSCT were observed in both arms. However, these deteriorations were not clinically meaningful in patients randomized to DEC, whereas this was the case for those in the 3+7 arm, in 4 of 5 primary HRQoL scales. Our HRQoL findings suggest that lower-intensity treatment with DEC may be preferable to current standard IC (3+7) in fit older patients with AML. This trial was registered at www.clinicaltrials.gov as #NCT02172872.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。